C 18 H 16 F 2 N 2 O 2 , monoclinic, P21/c (no. 14), a = 11.619(3) Å, b = 9.481(2) Å, c = 14.555(3) Å, β = 98.799(4)°, V = 1584.6(6) Å 3 ,
. 
Source of material
The title compound was synthesized according to a reported procedure [6] . A mixture of 3,5-cyclohexanedione (10 mmol), 3,5-di uorobenzaldehyde (10 mmol), malononitrile (10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1 mmol) in ethanol (100 mL) was re uxed for 2-3 h and then cooled to room temperature. After ltering the precipitate, it was sequentially washed with ice-cooled water and ethanol and then dried under a vacuum.
Experimental details
Carbon-bound and Nitrogen-bound H atoms were placed in calculated positions and were included in the re nement in the riding model approximation, with U iso (H) set to 1.2Ueq(C).
Discussion
The importance of the pyranyl moiety has been well proved as illustrated by a large number of patents, as chemotherapeutic agents [1, 2] . A number of biological activities have been associated with these compounds, such as antihypertensive, antiasthemic, analgesic, cardiovascular, platelate aggregation inhibitor and Ca antagonist [3, 4] . With this in mind, some new pyran derivatives have been synthesized in search of better therapeutic agents, by a convenient single pot method [5] .
In the crystal structure of the title compound, the 4H-pyran ring is nearly planar whereas the directly attached ring containing the keto group is folded. The plane of the 4H-pyran ring is almost perpendicular to the plane of the di uorphenyl moiety. All bond lengths and angles are in the expected ranges.
